Renaissance Technologies
LSTA icon

Renaissance Technologies’s Lisata Therapeutics LSTA Stock Holding History

Renaissance Technologies’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$660K Buy
131,715
+8,000
+6% +$33K ﹤0.01% 2482
2025
Q4 		$230K Buy
123,715
+7,093
+6% +$15.8K ﹤0.01% 2850
2025
Q3 		$306K Buy
116,622
+13,800
+13% +$34.6K ﹤0.01% 2985
2025
Q2 		$298K Buy
102,822
+100
+0.1% +$240 ﹤0.01% 3042
2025
Q1 		$241K Buy
102,722
+1,400
+1% +$3.79K ﹤0.01% 3007
2024
Q4 		$302K Sell
101,322
-2,300
-2% -$6.58K ﹤0.01% 3042
2024
Q3 		$311K Buy
103,622
+2,000
+2% +$6.3K ﹤0.01% 2966
2024
Q2 		$353K Buy
101,622
+2,100
+2% +$6.39K ﹤0.01% 2849
2024
Q1 		$311K Buy
99,522
+2,300
+2% +$6.81K ﹤0.01% 3077
2023
Q4 		$265K Buy
97,222
+1,500
+2% +$3.52K ﹤0.01% 3036
2023
Q3 		$205K Buy
95,722
+2,400
+3% +$6.67K ﹤0.01% 3087
2023
Q2 		$345K Buy
93,322
+900
+1% +$3.27K ﹤0.01% 3070
2023
Q1 		$300K Buy
92,422
+300
+0.3% +$1K ﹤0.01% 3120
2022
Q4 		$233K Sell
92,122
-8,800
-9% -$32.3K ﹤0.01% 3350
2022
Q3 		$467K Sell
100,922
-7,317
-7% -$53.1K ﹤0.01% 2963
2022
Q2 		$861K Buy
108,239
+7,749
+8% +$63.8K ﹤0.01% 2813
2022
Q1 		$1.09M Sell
100,490
-6,220
-6% -$71.2K ﹤0.01% 2675
2021
Q4 		$1.35M Sell
106,710
-9,760
-8% -$151K ﹤0.01% 2436
2021
Q3 		$2.13M Buy
116,470
+12,281
+12% +$241K ﹤0.01% 2039
2021
Q2 		$2.52M Buy
104,189
+6,845
+7% +$162K ﹤0.01% 2091
2021
Q1 		$2.82M Buy
97,344
+27,620
+40% +$837K ﹤0.01% 2001
2020
Q4 		$1.5M Buy
69,724
+7,907
+13% +$188K ﹤0.01% 2295
2020
Q3 		$1.67M Buy
61,817
+4,551
+8% +$144K ﹤0.01% 2239
2020
Q2 		$1.53M Buy
57,266
+28,801
+101% +$847K ﹤0.01% 2327
2020
Q1 		$769K Buy
28,465
+1,038
+4% +$40.3K ﹤0.01% 2552
2019
Q4 		$1.03M Buy
27,427
+1,304
+5% +$46.9K ﹤0.01% 2616
2019
Q3 		$1.01M Buy
26,123
+767
+3% +$29.8K ﹤0.01% 2587
2019
Q2 		$867K Buy
25,356
+4,333
+21% +$193K ﹤0.01% 2747
2019
Q1 		$1.14M Buy
21,023
+1,350
+7% +$88.7K ﹤0.01% 2609
2018
Q4 		$1.05M Buy
19,673
+949
+5% +$66K ﹤0.01% 2548
2018
Q3 		$1.66M Buy
18,724
+5,620
+43% +$461K ﹤0.01% 2369
2018
Q2 		$1.27M Buy
13,104
+3,301
+34% +$233K ﹤0.01% 2497
2018
Q1 		$859K Buy
9,803
+2,706
+38% +$187K ﹤0.01% 2718
2017
Q4 		$374K Sell
7,097
-133
-2% -$6.68K ﹤0.01% 2960
2017
Q3 		$388K Buy
7,230
+147
+2% +$8.92K ﹤0.01% 2848
2017
Q2 		$494K Buy
7,083
+580
+9% +$41K ﹤0.01% 2772
2017
Q1 		$491K Buy
6,503
+1,660
+34% +$115K ﹤0.01% 2776
2016
Q4 		$206K Buy
4,843
+2,900
+149% +$167K ﹤0.01% 2996
2016
Q3 		$135K Buy
1,943
+1,861
+2,270% +$150K ﹤0.01% 3137
2016
Q2 		$7K Buy
+82
New +$7.54K ﹤0.01% 3294
2013
Q4 		– Sell
-200
Closed -$257K – 2948
2013
Q3 		$257K Buy
+200
New +$222K ﹤0.01% 2508

Other funds holding LSTA

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 58.96% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCM
PenderFund Capital Management Vancouver, British Columbia, Canada $639M AUM 31.05% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return

Renaissance Technologies's LSTA Position: Q1 2026 in Review

Renaissance Technologies increased its Lisata Therapeutics (LSTA) stake by 6.5% in Q1 2026, buying an estimated $33K and bringing the position to 131,715 shares worth $660K. The position accounts for ﹤0.01% of the portfolio, ranked #2482.

Renaissance Technologies first reported a position in LSTA in Q3 2013 and has held it in 41 quarters since. The position peaked at $2.82M in Q1 2021. 34 funds tracked by Wall St. Rank hold LSTA as of Q1 2026.

  • Renaissance Technologies held 131,715 shares of Lisata Therapeutics worth $660K as of Q1 2026.
  • Renaissance Technologies bought 8,000 Lisata Therapeutics shares in Q1 2026, an estimated $33K.
  • Lisata Therapeutics made up ﹤0.01% of Renaissance Technologies's portfolio in Q1 2026, its #2482 holding.
  • Renaissance Technologies first reported a position in Lisata Therapeutics in Q3 2013 and has held it in 41 quarters since.
  • Renaissance Technologies's Lisata Therapeutics position peaked at $2.82M in Q1 2021.
  • 34 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.